Home › Urothelial (Transitional Cell) Carcinoma
Urothelial (Transitional Cell) Carcinoma clinical trials recruiting in the U.S.
74 studies for Urothelial (Transitional Cell) Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Nashville, TN24 studies
- New York City, NY22 studies
- Houston, TX20 studies
- Edison, NJ18 studies
- Dallas, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY16 studies
- Chicago, IL14 studies
- Boston, MA13 studies
- Arlington, VA13 studies
- San Antonio, TX13 studies
- Austin, TX10 studies
- Orlando, FL10 studies
- Philadelphia, PA10 studies
- Washington, DC10 studies
- St. Louis, MO10 studies
- Orange, CA9 studies
- Columbus, OH9 studies
- Durham, NC8 studies
- Jacksonville, FL8 studies
- Irvine, CA8 studies
- Seattle, WA8 studies
- Baldwin Park, CA8 studies
- Cleveland, OH7 studies
- Milwaukee, WI7 studies
- Portland, OR7 studies
- Omaha, NE7 studies
- Denver, CO7 studies
- Oklahoma City, OK7 studies
- Staten Island, NY7 studies
- Greenburgh, NY7 studies
- New Rochelle, NY7 studies
- Atlanta, GA7 studies
- Cedar Rapids, IA7 studies
- New Haven, CT6 studies
- Detroit, MI6 studies
- Gainesville, FL6 studies
- Phoenix, AZ6 studies
- Miami, FL6 studies
- Charlottesville, VA6 studies
By state
- Alabama5 studies
- Arizona10 studies
- Arkansas6 studies
- California32 studies
- Colorado12 studies
- Connecticut7 studies
- District of Columbia8 studies
- Florida25 studies
- Georgia10 studies
- Idaho4 studies
- Illinois21 studies
- Indiana6 studies
- Iowa8 studies
- Kansas3 studies
- Kentucky3 studies
- Louisiana4 studies
- Maryland8 studies
- Massachusetts17 studies
- Michigan16 studies
- Minnesota7 studies
- Missouri12 studies
- Montana3 studies
- Nebraska7 studies
- Nevada3 studies
- New Jersey22 studies
- New York29 studies
- North Carolina15 studies
- Ohio16 studies
- Oklahoma9 studies
- Oregon8 studies
- Pennsylvania16 studies
- South Carolina8 studies
- South Dakota3 studies
- Tennessee27 studies
- Texas41 studies
- Utah5 studies
- Virginia22 studies
- Washington13 studies
- Wisconsin10 studies
Recently updated studies
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06524544Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06695845A Study of GEN1106 in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07416123Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06396533Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07908979Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07566156DBC-664 in Adult Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07705035A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07287995Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06582017GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT04977453Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 16, 2026 · NCT06161532Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07749586Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07484022Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07421700A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT07218380Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07789119Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.